On November 12, 2015 ECRC, LLC and Amrita Therapeutics Limited reported collaboration on regulatory and drug development strategy for AT-01C, a p53 (tumor suppressor activator) compound with antimetastasis activity (Press release, Amrita Therapeutics, NOV 12, 2015, View Source [SID:1234512735]). Dr. Tomasz H. Zastawny, ECRC President and CEO, said: "We are delighted that Amrita has chosen ECRC as its US partner to advance AT-01 to the clinic. This is an ideal collaboration, combining my personal and ECRC’s expertise of PRA, one of the leading New England consultancy groups, with Amrita’s proprietary research platform. Together, we can accelerate Amrita’s pipeline development to bring the effective oncology treatment to the patients who need them in the US, India and globally."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under this agreement, ECRC and Amrita will collaborate on Pre-IND regulatory and early clinical development of AT-01C and other products. Amrita’s patent-protected peptides demonstrate antiinflammatory, p53 (tumor suppression) and anti-metastasis properties through stabilitzation of the SMAR1 protein and down-regulation of oncogenes. Therapeutics’s lead oncology peptide AT-01C shows effectiveness against colorectal, bladder and liver cancer, and is non-toxic to healthy tissues.